Antoine F Carpentier
Overview
Explore the profile of Antoine F Carpentier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
4680
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larue M, Bouvier A, Maillard A, Cuffel A, Allain V, Ursu R, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39317455
Immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant cause of morbidity associated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy. Early prediction of patients who will develop ICANS would...
2.
Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, et al.
Eur J Cancer
. 2023 Jun;
189:112913.
PMID: 37277265
Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with...
3.
Cuzzubbo S, Roch B, Darrasse-Jeze G, Hosten B, Leclercq M, Vignal N, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499300
We previously reported that a novel peptide vaccine platform, based on synthetic melanin nanoaggregates, triggers strong cytotoxic immune responses and significantly suppresses tumor growth in mice. However, the mechanisms underlying...
4.
Montegut C, Guillamo J, Ducray F, Dehais C, Moyal E, Desenclos C, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428602
Background: Describe the characteristics, patterns of care, and predictive geriatric factors of elderly patients with IDHm high-grade glioma (HGG) included in the French POLA network. Material and Methods: The characteristics...
5.
Cuzzubbo S, Carpentier A
Curr Opin Neurol
. 2022 Oct;
35(6):814-822.
PMID: 36226705
Purpose Of Review: We review the recent advances in neurological toxicities of immune checkpoint inhibitors, with a focus on underlying pathophysiologic mechanisms and the implications on their therapeutical management. Recent...
6.
Ursu R, Maillet D, Belin C, Moroni C, Cuzzubbo S, Vernier V, et al.
Neurology
. 2022 Jul;
99(12):511-515.
PMID: 35851255
Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a promising treatment in relapsing B-cell lymphoma but is frequently associated with acute neurotoxicity. Neurologic long-term safety has not been thoroughly...
7.
Omuro A, Brandes A, Carpentier A, Idbaih A, Reardon D, Cloughesy T, et al.
Neuro Oncol
. 2022 Apr;
25(1):123-134.
PMID: 35419607
Background: Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter...
8.
Jiguet-Jiglaire C, Boissonneau S, Denicolai E, Hein V, Lasseur R, Garcia J, et al.
Acta Neuropathol Commun
. 2022 Jan;
10(1):1.
PMID: 34980260
We previously identified matrix metalloproteinase 2 (MMP2) and MMP9 plasma levels as candidate biomarkers of bevacizumab activity in patients with recurrent glioblastoma. The aim of this study was to assess...
9.
Yap T, Vieito M, Baldini C, Sepulveda-Sanchez J, Kondo S, Simonelli M, et al.
Clin Cancer Res
. 2021 Sep;
27(24):6666-6676.
PMID: 34548321
Purpose: A novel, selective, next-generation transforming growth factor beta (TGFβ) receptor type-1 small molecule inhibitor, LY3200882, demonstrated promising preclinical data. This first-in-human trial evaluated safety, tolerability, recommended phase II dose...
10.
Maillet D, Belin C, Moroni C, Cuzzubbo S, Ursu R, Sirven-Villaros L, et al.
Neuro Oncol
. 2021 Apr;
23(9):1569-1575.
PMID: 33822183
Background: Chimeric antigen receptor-modified T (CAR T) cells are profoundly changing the standard of care in B-cell malignancies. This new therapeutic class induces a significant number of acute neurotoxicity, but...